Sartorius Stedim Biotech

DIM

FR0013154002

Medical Equipment, Supplies & Distribution

Market Closed - Euronext Paris Other stock markets 11:35:08 2024-04-24 am EDT			After market 12:58:42 pm
208.3 ^EUR	-0.19%		208.1	-0.10%

Apr. 23	SARTORIUS STEDIM BIOTECH : Barclays reaffirms its Neutral rating	ZD
Apr. 22	Sartorius Stedim: in the red with brokerage comments	CF

SARTORIUS STEDIM BIOTECH : Gets a Buy rating from JP Morgan

January 29, 2021 at 01:58 am EST

In a research note, JP Morgan analyst Richard Vosser has maintained his recommendation on the stock with a Buy rating. The target price is increased from EUR 350 to EUR 400.

Latest news about Sartorius Stedim Biotech

SARTORIUS STEDIM BIOTECH : Barclays reaffirms its Neutral rating	Apr. 23	ZD
Sartorius Stedim: in the red with brokerage comments	Apr. 22	CF
UBS Cuts Sartorius Stedim Biotech PT, Maintains at Neutral	Apr. 22	MT
SARTORIUS STEDIM BIOTECH : Q1 24: A few positives despite the top-line miss	Apr. 22
SARTORIUS STEDIM : UBS reduces target price	Apr. 22	CF
Global markets live: DocMorris, Microsoft, Oracle, Micron, Netflix...	Apr. 18
Transcript : Sartorius Stedim Biotech S.A., Q1 2024 Earnings Call, Apr 18, 2024	Apr. 18
Transcript : Sartorius Aktiengesellschaft, Sartorius Stedim Biotech S.A., Q1 2024 Earnings Call, Apr 18, 2024	Apr. 18
Sartorius and subsidiary Stedim under pressure after weak figures	Apr. 18	DP
U.S. Futures, European Stocks Rise	Apr. 18	DJ
Sartorius Stedim: Quarterly EPS more than halved	Apr. 18	CF
Sartorius Stedim Biotech S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 18	CI
Sartorius Stedim Biotech Records Lower Q1 Attributable Net Profit, Sales Revenue	Apr. 18	MT
Transcript : Sartorius Stedim Biotech S.A. - Shareholder/Analyst Call	Mar. 26
SARTORIUS STEDIM BIOTECH : Jefferies remains its Buy rating	Mar. 12	ZD
Berenberg: Sartorius Stedim Investors Await 'Several Strong Quarters' for Confidence Boost	Feb. 16	MT
Sartorius gains despite halving dividend	Feb. 09	DP
Sartorius Stedim Biotech S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 08	CI
Sartorius Stedim: dividend set for 2023	Feb. 08	CF
Dpa-AFX Overview: COMPANIES from 07.02.2024 - 15:15	Feb. 07	DP
Debt reduction: Sartorius sells shares - Stedim with capital increase	Feb. 07	DP
Sartorius Stedim Biotech Shares Fall After Capital Increase	Feb. 07	DJ
Sartorius Stedim Biotech Completes $1.3 Billion Capital Increase	Feb. 07	DJ
Sartorius Stedim: private placement of 5.15 million shares	Feb. 07	CF
Germany's Sartorius Raises EUR200 Million Via Share Issue	Feb. 07	MT

Chart Sartorius Stedim Biotech

Duration

Period

More charts

Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. For next generation processes, Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of turning science into solutions on a daily basis. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-16 - Capital Markets Day

Related indices

STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

SARTORIUS STEDIM BIOTECH : Q1 24: A few positives despite the top-line miss

April 22, 2024 at 07:56 am EDT

More Strategies

Ratings for Sartorius Stedim Biotech

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

208.7 EUR

Average target price

251.3 EUR

Spread / Average Target

+20.43%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
SARTORIUS STEDIM BIOTECH	-13.03%	21.73B
ABBOTT LABORATORIES	-3.22%	187B
MEDTRONIC PLC	-2.37%	108B
BECTON, DICKINSON AND COMPANY	-4.08%	67.71B
DEXCOM, INC.	+9.58%	53.07B
CENCORA, INC.	+15.71%	47.36B
HOYA CORPORATION	+6.01%	39.73B
WEST PHARMACEUTICAL SERVICES, INC.	+9.99%	28.56B
METTLER-TOLEDO INTERNATIONAL, INC.	+1.36%	26.55B
TERUMO CORPORATION	+15.97%	25.13B

Other Medical Equipment, Supplies & Distribution